NasdaqGM - Nasdaq Real Time Price USD
Altimmune, Inc. (ALT)
As of 1:35 PM EST. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Vipin K. Garg Ph.D. | President, CEO & Director | 986.14k | -- | 1958 |
| Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS | Chief Medical Officer | 681.81k | -- | 1953 |
| Mr. Raymond M. Jordt M.B.A. | Chief Business Officer | 578.85k | -- | 1973 |
| Mr. Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer | -- | -- | 1956 |
| Mr. Andrew Shutterly M.S. | Principal Financial & Accounting Officer and Corporate Controller | -- | -- | 1988 |
| Mr. Bertrand Georges Ph.D. | Chief Technology Officer | -- | -- | -- |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer | 599.25k | -- | 1959 |
| Mr. Tony Blandin B.S. | Vice President of Quality & Compliance Management | -- | -- | -- |
Altimmune, Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 59
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Corporate Governance
Altimmune, Inc.’s ISS Governance QualityScore as of November 1, 2024 is 7. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 4; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 12, 2024 at 12:00 PM UTC
Altimmune, Inc. Earnings Date
Recent Events
Related Tickers
VKTX Viking Therapeutics, Inc.
53.81
+4.42%
MDGL Madrigal Pharmaceuticals, Inc.
327.94
+3.42%
IOVA Iovance Biotherapeutics, Inc.
8.32
+2.21%
TERN Terns Pharmaceuticals, Inc.
5.77
+2.95%
TGTX TG Therapeutics, Inc.
35.02
+12.42%
IBRX ImmunityBio, Inc.
5.10
+4.51%
SAVA Cassava Sciences, Inc.
31.86
+22.29%
GPCR Structure Therapeutics Inc.
31.23
-4.53%
NTLA Intellia Therapeutics, Inc.
14.35
+9.38%
SMMT Summit Therapeutics Inc.
19.09
+2.52%